IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...
5h
Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...
Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Researchers at the University of Toronto’s Institute of Biomedical Engineering have found that studying blood flow in leg muscles may help detect cardiovascular disease earlier than standardized tests ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...
Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...
AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
Mair Therapeutics Secures Pre-Seed Funding and Launches to Pioneer Therapies for Parkinson's Disease
Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA , and Oost NL, a regional development agency supporting innovation-driven companies, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback